Related Experiment Videos
Rituximab in B-cell chronic lymphocytic leukemia
Thomas S Lin1, Margaret S Lucas, John C Byrd
1The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH, USA.
Seminars in Oncology
|August 27, 2003
Summary
Rituximab shows less efficacy in B-chronic lymphocytic leukemia (B-CLL) as a single agent. Combination therapy, like with fludarabine, and dose escalation improve its effectiveness in treating B-CLL.
Area of Science:
- Oncology
- Immunology
Background:
- Rituximab, a monoclonal anti-CD20 antibody, targets cellular defects in apoptosis contributing to B-chronic lymphocytic leukemia (B-CLL).
- Initial Phase II studies indicated limited single-agent activity of rituximab in B-CLL compared to indolent B-cell lymphomas.
Purpose of the Study:
- To evaluate the efficacy of rituximab in B-CLL, exploring dose escalation and combination regimens.
- To assess the safety and tolerability of rituximab in B-CLL patients.
Main Methods:
- A multicenter, prospective, randomized trial compared rituximab with fludarabine to standard treatments.
- Ongoing studies investigate combination regimens such as FCR (fludarabine, cyclophosphamide, rituximab).
- Infusion toxicity, including tumor lysis syndrome, was monitored.
Main Results:
- Dose escalation with a thrice-weekly schedule enhances rituximab's single-agent activity in B-CLL.
- Concurrent administration with fludarabine significantly improves the complete response (CR) rate.
- The FCR regimen shows promising results in early-phase trials.
Conclusions:
- Optimized dosing schedules and combination therapies are crucial for effective rituximab use in B-CLL.
- While infusion toxicities like tumor lysis syndrome can occur, they are manageable with appropriate premedication and dose escalation.
- Rituximab can be used safely and effectively in B-CLL treatment with careful management.